Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
289 hedge funds and large institutions have $2.85B invested in Amedisys in 2024 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 93 increasing their positions, 104 reducing their positions, and 31 closing their positions.
35% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 31
18% more funds holding in top 10
Funds holding in top 10: 11 → 13 (+2)
2% more funds holding
Funds holding: 283 → 289 (+6)
0.07% more ownership
Funds ownership: 94.92% → 94.99% (+0.07%)
0% less capital invested
Capital invested by funds: $2.86B → $2.85B (-$5.79M)
11% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 104
82% less call options, than puts
Call options by funds: $17.1M | Put options by funds: $94.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$96.9M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$27.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.4M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$18.5M |
| 5 |
SGCM
Sand Grove Capital Management
London,
United Kingdom
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$32.3M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$29.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$19.5M |
| 4 |
MAM
Melqart Asset Management
London,
United Kingdom
|
-$18.9M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$18.3M |
AMED Hedge Fund Activity: Q2 2024 in Review
289 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2024, worth a combined $2.85B — down 0.2% from $2.86B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new AMED positions and 31 closed out — a net gain of 11 holders — while 93 added to existing stakes and 104 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $96.9M. The largest seller was Millennium Management, cutting an estimated $32.3M.
- 289 institutional investors held Amedisys (AMED) as of Q2 2024, up from 283 in Q1 2024.
- Funds reported $2.85B of Amedisys stock for Q2 2024, down 0.2% quarter-over-quarter.
- 42 funds opened new Amedisys positions in Q2 2024 and 31 closed out, a net change of +11 holders.
- The largest Amedisys buyer in Q2 2024 was Goldman Sachs, an estimated $96.9M added.
- The largest Amedisys seller in Q2 2024 was Millennium Management, an estimated $32.3M sold.
Based on aggregated 13F filings for Q2 2024.